Elanco Animal Health Incorporated
HealthcareNYSE:ELAN · New York Stock Exchange
+$0.14 today
Vol 2.22M · Avg 6.11M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$232.0M -168.6% | $338.0M +127.5% | -$1.2B -1478.2% | -$78.0M +83.5% | -$472.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $680.0M +2.7% | $662.0M -4.6% | $694.0M +1.8% | $682.0M -4.7% | $716.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$134.0M -19.6% | -$112.0M -40.0% | -$80.0M -40.4% | -$57.0M +63.0% | -$154.0M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $68.0M +23.6% | $55.0M +19.6% | $46.0M -22.0% | $59.0M -10.6% | $66.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $99.0M -33.6% | $149.0M +149.7% | -$300.0M +35.1% | -$462.0M -431.0% | -$87.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$12.0M -200.0% | $12.0M +130.0% | -$40.0M -385.7% | $14.0M +566.7% | -$3.0M | $592.6M | $1.3B | $626.2M |
| Inventory | -$57.0M -229.5% | $44.0M +127.5% | -$160.0M +40.5% | -$269.0M -1096.3% | $27.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $147.0M +79.3% | $82.0M +187.2% | -$94.0M +4.1% | -$98.0M +18.3% | -$120.0M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $21.0M +90.9% | $11.0M +283.3% | -$6.0M +94.5% | -$109.0M -1311.1% | $9.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $79.0M +114.3% | -$551.0M -148.2% | $1.1B +270.8% | $308.0M -25.6% | $414.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $560.0M +3.5% | $541.0M +99.6% | $271.0M -40.0% | $452.0M -6.4% | $483.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$276.0M -87.8% | -$147.0M +4.5% | -$154.0M +16.3% | -$184.0M +6.6% | -$197.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 -100.0% | $1.3B +7042.1% | -$19.0M -246.2% | $13.0M +103.8% | -$342.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$3.0M +78.6% | -$14.0M -40.0% | -$10.0M -25.0% | -$8.0M -188.9% | $9.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$279.0M -124.1% | $1.2B +785.2% | -$169.0M +5.6% | -$179.0M +66.2% | -$530.0M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$563.0M +61.8% | -$1.5B -1815.6% | -$77.0M +85.1% | -$517.0M -392.1% | $177.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $288.0M +1794.1% | -$17.0M -183.3% | -$6.0M +81.3% | -$32.0M -197.0% | $33.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$275.0M +81.6% | -$1.5B -1697.6% | -$83.0M +84.9% | -$549.0M -361.4% | $210.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $71.0M +178.0% | -$91.0M -658.3% | -$12.0M +29.4% | -$17.0M +45.2% | -$31.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $77.0M -33.6% | $116.0M +1557.1% | $7.0M +102.4% | -$293.0M -322.0% | $132.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $284.0M -27.9% | $394.0M +236.8% | $117.0M -56.3% | $268.0M -6.3% | $286.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.74B
Viatris Inc.
NASDAQ:VTRS
$19.10B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.18B
Solventum Corporation
NYSE:SOLV
$13.53B
Align Technology, Inc.
NASDAQ:ALGN
$12.50B
Revvity, Inc.
NYSE:RVTY
$11.13B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.11B
Encompass Health Corporation
NYSE:EHC
$10.07B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.69B
Qiagen N.V.
NYSE:QGEN
$7.65B
SEC Filings
Recent regulatory filings
No filings found.
Does ELAN generate free cash flow?
Elanco Animal Health Incorporated (ELAN) generated $284.00M of free cash flow in fiscal 2025.
How much operating cash flow does ELAN produce?
Operating cash flow was $560.00M, before capital expenditures of $276.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.